奇点网免疫治疗革命，始于一位蓝调音乐家从癌细胞手中抢过手刹( 四 )

本文插图
就在这个月， ipilimumab + nivolumab联合治疗再次获批新适应症，用于一线治疗转移性非小细胞肺癌（图片来源：FDA官网）
能够在联合治疗中获益的患者还将增加，例如在去年美国癌症研究协会（AACR）年会上公布最新结果的神经内分泌瘤[21] 。
“我认为做科学研究，最重要的是要去叩问那些最根本而又至关重要的问题。并且你需要时不时地，给自己倒上一杯酒，把脚放在桌子上，然后问：我们如何更好地利用这些知识和发现。 ”
这不仅是Allison教授给科学研究者的建议，更是他对几十年来卓越工作的精辟阐释。癌症免疫治疗的路还很长， Allison和他的朋友们仍旧在努力着。
PS：Allison教授的车牌号是CTLA-4 。
*目前尚无CTLA-4抑制剂在中国大陆获批
参考资料：
[1]https://www.drugs.com/newdrugs/fda-approves-yervoy-late-stage-melanoma-2569.html
[2]http://www.whatisbiotechnology.org/index.php/people/summary/Allison
[3]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607124/
[4] Walunas T L, Lenschow D J, Bakker C Y, et al. CTLA-4 can function as a negative regulator of T cell activation[J]. Immunity, 1994, 1(5): 405-413.
[5] Waterhouse P, Penninger J M, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4[J]. Science, 1995, 270(5238): 985-988.
[6] Tivol E A, Borriello F, Schweitzer A N, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4[J]. Immunity, 1995, 3(5): 541-547.
[7]Buchbinder E I, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. American journal of clinical oncology, 2016, 39(1): 98.
[8]Leach D R, Krummel M F, Allison J P. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science, 1996, 271(5256): 1734-1736.
[9]Ipilimumab. Drugs R&D. 2012;10(2):97–110.
[10]Hodi F S, O'Day S J, McDermott D F, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. New England Journal of Medicine, 2010, 363(8): 711-723.
[11]http://nautil.us/issue/65/in-plain-sight/the-rise-of-cancer-immunotherapy
[12]https://www.ecco-org.eu/Amsterdam2013/Global/News/ECC-2013-Press-Releases-EN/2013/09/Longest-follow-up-of-largest-number-of-melanoma-patients
[13] Garbe C, Eigentler T K, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects[J]. The oncologist, 2011, 16(1): 5-24.
[14] Postow M A, Chesney J, Pavlick A C, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J]. New England Journal of Medicine, 2015, 372(21): 2006-2017.
[15]https://www.drugs.com/newdrugs/bms-receives-fda-approval-opdivo-nivolumab-yervoy-ipilimumab-regimen-braf-v600-wild-type-melanoma-4271.html
[16]https://www.drugs.com/newdrugs/bristol-myers-squibb-s-opdivo-nivolumab-yervoy-ipilimumab-regimen-receives-expanded-fda-approval-4332.html
[17]https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm
[18]https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm613227.htm

奇点网 免疫治疗革命，始于一位蓝调音乐家从癌细胞手中抢过手刹( 四 )

奇点网免疫治疗革命，始于一位蓝调音乐家从癌细胞手中抢过手刹( 四 )